Indivior Pharmaceuticals (INDV) Total Debt (2021 - 2026)

Indivior Pharmaceuticals' Total Debt history runs 6 years deep, the most recent figure standing at $486.0 million for Q1 2026.

• On a quarterly basis, Total Debt rose 47.72% year-over-year to $486.0 million in Q1 2026; TTM through Mar 2026 was $486.0 million, a 47.72% increase from a year earlier, with the FY2025 full-year figure at $319.0 million, down 4.2% from the prior year.
• Total Debt rose to $486.0 million in Q1 2026 per INDV's latest filing, from $319.0 million in the prior quarter.
• Across five years, Total Debt topped out at $486.0 million in Q1 2026 and bottomed at $240.0 million in Q4 2022.
• The 5-year median for Total Debt is $324.0 million (2025), against an average of $324.4 million.
• Across the five-year window, Total Debt retreated 4.2% in 2025 and surged 47.72% in 2026, its largest moves.
• Year by year, Total Debt stood at $240.0 million in 2022, then changed by 0.0% to $240.0 million in 2023, then jumped by 38.75% to $333.0 million in 2024, then declined by 4.2% to $319.0 million in 2025, then soared by 52.35% to $486.0 million in 2026.
• Per Business Quant, the three latest INDV Total Debt figures stand at $486.0 million (Q1 2026), $319.0 million (Q4 2025), and $322.0 million (Q3 2025).